Literature DB >> 8095437

Typhlitis resulting from treatment with taxol and doxorubicin in patients with metastatic breast cancer.

B C Pestalozzi1, G A Sotos, P L Choyke, J S Fisherman, K H Cowan, J A O'Shaughnessy.   

Abstract

BACKGROUND: Typhlitis is being recognized with increasing frequency as a serious complication of aggressive chemotherapy for hematologic and solid malignancies.
METHODS: In this report the authors describe two cases of typhlitis in patients with metastatic breast cancer treated with taxol and doxorubicin.
RESULTS: Both cases occurred during the first cycle of treatment with taxol (180 mg/m2) and doxorubicin (75 mg/m2), being given simultaneously as 72-hour continuous intravenous infusions.
CONCLUSION: Two cases of typhlitis have occurred after combined treatment with taxol and doxorubicin, while typhlitis has not been described after treatment with either drug alone.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8095437     DOI: 10.1002/1097-0142(19930301)71:5<1797::aid-cncr2820710514>3.0.co;2-b

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

Review 1.  Necrotizing enterocolitis in neutropenia and chemotherapy: a clinical update and old lessons relearned.

Authors:  CelesteAnn T Bremer; Brian P Monahan
Journal:  Curr Gastroenterol Rep       Date:  2006-08

Review 2.  Risks and benefits of taxanes in breast and ovarian cancer.

Authors:  L B Michaud; V Valero; G Hortobagyi
Journal:  Drug Saf       Date:  2000-11       Impact factor: 5.606

Review 3.  Neutropenic enterocolitis in adults: case series and review of the literature.

Authors:  Steven C Cunningham; Karim Fakhry; Barbara L Bass; Lena M Napolitano
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

4.  Aptamer-mediated selective delivery of a cytotoxic cationic NHC-Au(i) complex to cancer cells.

Authors:  Weijia Niu; I-Ting Teng; Xigao Chen; Weihong Tan; Adam S Veige
Journal:  Dalton Trans       Date:  2017-12-19       Impact factor: 4.390

5.  N-Heterocyclic Carbene-Gold(I) Complexes Conjugated to a Leukemia-Specific DNA Aptamer for Targeted Drug Delivery.

Authors:  Weijia Niu; Xigao Chen; Weihong Tan; Adam S Veige
Journal:  Angew Chem Int Ed Engl       Date:  2016-06-17       Impact factor: 15.336

Review 6.  Current status of paclitaxel in the treatment of breast cancer.

Authors:  J A O'Shaughnessy; K H Cowan
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

7.  Clinical trials and progress with paclitaxel in ovarian cancer.

Authors:  Sanjeev Kumar; Haider Mahdi; Christopher Bryant; Jay P Shah; Gunjal Garg; Adnan Munkarah
Journal:  Int J Womens Health       Date:  2010-11-19

8.  Altered gut microbiome promotes proteinuria in mice induced by Adriamycin.

Authors:  Qian Jiang; Xiwei He; Yuntao Zou; Yin Ding; Huang Li; Huimei Chen
Journal:  AMB Express       Date:  2018-02-28       Impact factor: 3.298

9.  Alantolactone promotes ER stress-mediated apoptosis by inhibition of TrxR1 in triple-negative breast cancer cell lines and in a mouse model.

Authors:  Changtian Yin; Xuanxuan Dai; Xiangjie Huang; Wangyu Zhu; Xi Chen; Qiulin Zhou; Canwei Wang; Chengguang Zhao; Peng Zou; Guang Liang; Vinothkumar Rajamanickam; Ouchen Wang; Xiaohua Zhang; Ri Cui
Journal:  J Cell Mol Med       Date:  2019-01-04       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.